Encephalopathy:
Protecting the Injured Brain
What Is Encephalopathy?
‍Encephalopathy is a broad clinical term for brain disfunction caused by an insult that disrupts normal neurological function. In the context of Ardram's neurological programme, we address two primary presentations: 
Hypoxic-Ischaemic Encephalopathy (HIE): Brain injury caused by inadequate oxygen or blood supply — most commonly occurring at or around birth in neonates (birth asphyxia), or in adults following cardiac arrest, respiratory failure, or prolonged hypoxic events.
‍Acquired Encephalopathy: Brain dysfunction arising from traumatic brain injury, metabolic disturbance, infection (encephalitis), or inflammatory insult — resulting in disrupted consciousness, cognition, motor function, or seizure activity. 

The degree of injury spans a wide spectrum. Mild encephalopathy may manifest as altered alertness or feeding difficulties in neonates; severe cases involve significant motor impairment, epileptic encephalopathy, and impaired cognitivedevelopment. Outcomes depend critically on the extent of initial brain injury, the regions affected, and the speed and quality of subsequent neuro protective intervention.
White checkmark symbol inside a gold circular background.
Supporting neuroprotection
White checkmark symbol inside a gold circular background.
Promoting motor recovery
White checkmark symbol inside a gold circular background.
Reducing seizure burden
White checkmark symbol inside a gold circular background.
Complementing rehab
Understanding
Encephalopathy & Brain
Injury
Encephalopathy is a complex neurological state that describes any disease or injury that affects the function or structure of the brain. At Ardram, we focus on therapeutic interventions for Hypoxic-Ischaemic Encephalopathy (HIE) and Acquired Brain Injury (ABI).

Whether caused by oxygen deprivation at birth or trauma later in life, the result is often a cascade of cellular damage. Our clinical objective is to intervene in this cascade, promoting cellular stability and fostering a more favorable environment for neuro-regeneration and functional rehabilitation.
PRECISION ADMISSION
BEFORE TREATMENT BEGINS
Clinical Review Assessment Table
Assessment Area What is Reviewed
Medical/Injury History Full diagnostic review of the inciting event (HIE, stroke, trauma) and subsequent clinical course.
Neuroimaging Review of recent MRI/CT scans to understand lesion patterns and localized brain damage.
Implants/Devices Safety check for any ferromagnetic implants or electronic medical devices (VNS, shunts).
Active Conditions Current status of epilepsy/seizure frequency, nutritional stability, and respiratory health.
Current Treatment Ongoing medications and existing rehabilitation programs to ensure synergy with Cytotron therapy.
How RFQMR-FRB Therapy Works?
Cytotron addresses the threefold challenge of damaged neurons: metabolic dysfunction,
membrane instability, and impaired connectivity. By modulating specific biological
pathways, it creates a conducive environment for recovery.
Network diagram with a central circle connected to six outer circles by lines.
Hsp70 Neuroprotection
Heat Shock Protein 70 (Hsp70) is up regulated by RFQMR stimulation. In the context of hypoxic-ischaemic injury, Hsp70 acts as a molecular chaperone: it stabilises damaged proteins in surviving neurons, reduces ischaemic cell death in the penumbral zone, and extends the window for functional recovery. Critically, Hsp70 has been demonstrated to protect neurons against the apoptotic cascade triggered by the calcium surge that follows NMDA receptor activation in excitotoxic injury.
Network diagram with a central circle connected to six outer circles by lines.
Transmembrane Potential (TMP) Normalisation
Encephalopathic neurons exhibit chronically depolarised membranes — a state that sustains NMDA receptor activation, perpetuates the excitotoxic cascade, and lowers the seizure threshold. RFQMR-FRB directly modulates TMP across target neural tissue, normalising the electrochemical gradient. This reduces the ongoing excitotoxic drive, supports neuronal recovery, and contributes to cortical stabilisation — addressing the underlying biophysical driver of both neuronal death and seizure activity.
Network diagram with a central circle connected to six outer circles by lines.
VEGF — Vascular and Metabolic Recovery
Vascular Endothelial Growth Factor (VEGF) is up regulated by RFQMR stimulation, promoting angiogenesis — the formation of new blood vessels — in oxygen-deprived brain tissue. In HIE and acquired brain injury, restoration of cerebral perfusion is essential for metabolic recovery of damaged but viable neurons. Improved vascular supply delivers oxygen and glucose to regions at risk of secondary infarction, supporting tissue salvage in the subacute and recovery phases.
Network diagram with a central circle connected to six outer circles by lines.
BDNF and GDNF — Neurotrophic Support
RFQMR promotes controlled, therapeutic calcium influx through voltage-gated channels. This controlled signal activates calmodulin, which phosphorylates CREB (cAMP Response Element-Binding protein). Activated CREB drives gene transcription essential for synaptic plasticity and neural circuit repair. In encephalopathy, this pathway supports the formation of new functional connections that compensate for destroyed circuitry, enabling recovery of sensor imotor, cognitive, and language functions
Network diagram with a central circle connected to six outer circles by lines.
Ca²⁺-Calmodulin - CREB Pathway - Synaptic Repair
Brain-Derived Neurotrophic Factor (BDNF) and Glial Cell Line-Derived Neurotrophic Factor (GDNF) are up regulated during RFQMR therapy. BDNF promotes survival and strengthening of damaged neurons and supports long-term synaptic potentiation necessary for functional recovery. GDNF provides critical survival signalling to vulnerable neuronal populations in the injured brain. Together, these factors reduce ongoing neuronal loss and support the structural substrate on which functional recovery depends.
Network diagram with a central circle connected to six outer circles by lines.
MAPK/ERK —
Neural Progenitor Activation
The MAPK/ERK signalling cascade is stimulated by RFQMR-induced biophysical modulation. This pathway promotes the proliferation and differentiation of neural progenitor cells — the brain's resident cells.
What Improvement Looks Like
Neurological & Motor Recovery
Patients often show improvements in muscle tone, coordination, and voluntary motor control as synaptic pathways stabilize.
Seizure Burden Reduction
Many caregivers report a decrease in seizure frequency or intensity as cellular electrical stability is restored in the brain.
Cognitive and Developmental Progress
Enhancements in alertness, communication, and cognitive engagement, supporting overall developmental milestones in pediatric cases.
Neuroprotection
TMP Normalization
Seizure Management
Functional Recovery

Everything You Need
to Know—Upfront

We help patients and healthcare partners navigate personalized care and innovative medtech solutions—here’s what most people ask before getting started with us
What is Cytotron treatment for encephalopathy?

Cytotron is a non-invasive regenerativetechnology that uses RFQMR-FRB electromagnetic therapy to modulate cellularsignalling in damaged brain tissue. It is designed to support neuroprotection,reduce excitotoxic stress, promote neural circuit repair, and complementexisting medical management for hypoxic-ischaemic and acquired encephalopathy.

Can Cytotron help patients with HIE(hypoxic-ischaemic encephalopathy)?

Yes. RFQMR-FRB  therapy targets the core mechanisms of secondary brain injury in HIE —  excitotoxicity, mitochondrial failure, apoptosis, and impaired vascular  perfusion. Therapy is considered in both the subacute phase and longer-term  rehabilitation, following initial medical stabilisation. Eligibility is  determined through clinical assessment and MRI review.

Is Cytotron treatment  suitable for children with encephalopathy?

Cytotron is non-surgical, painless, and does notinvolve radiation, injections, or anaesthesia. Paediatric patients may undergotreatment with a parent or carer present throughout each session. Beforetreatment is confirmed, every patient undergoes a structured clinicalassessment by Ardram’s medical team covering medical history, neuroimaging,implants and devices (including VP shunts, cochlear implants, and cardiachardware), active medical conditions, and a systematic review ofcontraindications. Presence of an implant does not automatically excludetreatment, but must be disclosed and formally assessed. Eligibility is notassumed — it is determined by the clinical team.

Can Cytotron help with seizures inencephalopathy?

In patients  with epileptic encephalopathy or drug-resistant seizures secondary to brain  injury, RFQMR-FRB therapy aims to normalise the transmembrane potential  environment that sustains cortical hyperexcitability. Cytotron is used as a  complementary modality alongside existing anti-epileptic medication — it does  not require medication to be reduced or withdrawn. Response is monitored  through EEG and clinical outcome measures.

Can Cytotron be combined  with physiotherapy and rehabilitation?

Yes. Cytotron  is routinely integrated with physiotherapy, occupational therapy, speech and  language therapy, and cognitive rehabilitation. The regenerative effects of  RFQMR-FRB may enhance the brain's responsiveness to conventional  rehabilitation, supporting greater functional gains when both approaches are  used together.The number of sessions varies depending on the child’s condition, age, severity of symptoms, and rehabilitation goals after medical evaluation.

How quickly can I schedule an appointment?

Initial  clinical assessments can typically be arranged within a few days of enquiry,  including remote video consultation for international or out-of-station  patients. The assessment covers medical history, neuroimaging,
contraindication screening, and current clinical context. A treatment slot is confirmed only after the clinical team has completed the assessment and
determined suitability. Contact us at care@ardram.com or via the Enquire form  to begin the process.